Respiratory

• M&A / Deals

Avalyn, in pursuit of better lung drugs, banks $300M in an IPO

pharminent April 30, 2026

• M&A / Deals

Avalyn seeks public debut to support new lung drug formulations

pharminent April 24, 2026

• Clinical Data

AZ is three for three with COPD hope tozorakimab

pharminent April 20, 2026

• Other

Pulmonary fibrosis drug developer Avalyn files IPO

pharminent April 9, 2026

• Other

Avalyn plots IPO to push inhaled pulmonary fibrosis pipeline through clinic

pharminent April 9, 2026

• Pipeline

Insmed Scraps Skin Plans for Lung Disease Drug as Competitors Make Headway

pharminent April 8, 2026

• Clinical Data

AstraZeneca lung drug gets ‘surprise’ win in COPD trials

pharminent March 27, 2026